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ABSTRACT: Sialic acid sugars on mammalian cells regulate
numerous biological processes, while aberrant expression of
sialic acid is associated with diseases such as cancer and
pathogenic infection. Inhibition of the sialic acid biosynthesis
may therefore hold considerable therapeutic potential. To
effectively decrease the sialic acid expression, we synthesized
C-5-modified 3-fluoro sialic acid sialyltransferase inhibitors.
We found that C-5 carbamates significantly enhanced and prolonged the inhibitory activity in multiple mouse and human cell
lines. As an underlying mechanism, we have identified that carbamate-modified 3-fluoro sialic acid inhibitors are more efficiently
metabolized to their active cytidine monophosphate analogues, reaching higher effective inhibitor concentrations inside cells.
Sialic acids are a family of complex nine-carbon sugarsabundantly expressed at the termini of mammalian glycans
on cell-bound and secreted glycoproteins and glycolipids.1 The
negative charge of sialic acids can facilitate the binding and
transport of ions, enhance the viscosity of mucins, and stabilize
proteins and membranes. Additionally, they mask underlying
galactose residues, thereby regulating protein half-life2 and
recycling.1 Sialoglycans are recognized by sialic acid-binding
immunoglobulin-like lectins (Siglecs), a family of immunor-
egulatory receptors,3,4 and selectins that mediate trafficking of
immune cells.5 Although sialic acids play an important role in
numerous physiological processes, they are also associated with
several pathologies. For example, certain viruses (e.g.,
inf luenza) target sialoglycans to infect host cells6 and some
pathogenic bacteria (e.g., Pseudomonas) decorate their surface
with sialic acids to escape the host immune system.7
Additionally, overexpression of sialoglycans on the surface of
cancer cells has been indicated to mediate resistance to
apoptosis,8,9 support immune evasion,10 and facilitate meta-
static spread.11,12 Hence, in these cases, reducing the
(over)expression of sialic acid holds considerable therapeutic
potential. Lowering of sialic acid expression can be achieved by
the use of bacterial sialidases, enzymes that cleave sialic acids
from sialoglycans. However, bacterial sialidases are hard to
obtain with high purity, can be immunogenic, and their effect
is short-lived as intracellular sialoglycan biosynthesis is
unaffected.13,14 Small-molecule inhibitors of sialic acid biosyn-
thesis or glycan sialylation might overcome these issues.15,16 As
a target, sialyltransferases (STs) are especially promising as
they catalyze a late stage reaction in sialoglycan formation.
Inhibiting ST therefore affects both the de novo synthesis of
sialic acid and its salvage pathway. Furthermore, cancer cells
are frequently hypersialylated as a result of oncogene-induced
expression of STs.8 A family of 20 STs catalyze sialic acid
transfer to glycans inside the Golgi with substrate and linkage
specificity resulting in a variety of α2,3-, α2,6-, and α2,8-linked
sialic acid-containing glycans.1 This sialylation reaction can be
inhibited using a fluorinated sialic acid substrate [cytidine
monophosphate (CMP)−SiaFAc].17 Although closely resem-
bling the natural CMP−sialic acid substrate, a fluoride is
thought to destabilize the oxocarbenium transition state
needed for sialic acid transfer to penultimate carbohydrates
to occur.18,19 Additionally, accumulation of CMP−Sia induces
feedback inhibition of UDP-GlcNAc 2-epimerase/ManNAc
kinase (GNE), which is involved in N-acetylmannosamine
(ManNAc) biosynthesis, the metabolic precursor of sialic
acid.20,21 CMP−SiaFAc is, however, not cell-permeable and
hence not active in cell culture or suitable for use in vivo. This
hurdle was overcome by Paulson and co-workers by feeding a
peracetylated metabolic precursor (SiaFAc, 1) which enables
passive diffusion over the cell membrane (Figure 1a).22 Inside
the cell, SiaFAc is deacetylated by esterases and CMP-activated
by the CMP N-acetylneuraminic acid synthetase (CMAS) to
prepare the active CMP−SiaFAc. We and others have shown
that 1 inhibits sialylation with high specificity in cancer cells in
vitro and in vivo, resulting in reduced tumor growth and
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metastasis.23−26 During these studies, we found that the
sensitivity of different cell lines for SiaFAc varied from low
micromolar to high micromolar concentrations. These findings
prompted us to improve the inhibitory potency of the lead
compound SiaFAc by introducing modifications to the sialic
acid backbone (Figure 1b). It is well documented that C-5-
modified sialic acids are utilized as substrates by cells for the
sialylation reaction, and hence, this position was selected for
modification.27,28 We have designed and synthesized 17
different fluorinated sialic acid analogues and tested their
effects in multiple cell lines. We found that replacement of the
natural N-acetamide substituent by a carbamate drastically
improved the inhibitory activity of the lead compound. Several
of the carbamate analogues showed potent and long-lasting
inhibition of sialic acid expression in the low micromolar range
in both human and mouse cancer cell lines. Remarkably, the
carbamate-modified sialic acids also showed potent effects in
cancer cell lines with very poor sensitivity for the lead
compound SiaFAc (1). Investigation of the mechanism of
action in silico and in vitro showed that the carbamate-based
inhibitors are more efficiently metabolized toward their active
CMP analogues, reaching higher effective intracellular inhibitor
concentrations.
■ RESULTS AND DISCUSSION
Synthesis of C-5-Modified Fluorinated Sialic Acid
Analogues. The SiaFAc (1) derivatives 2−18 (Figure 1b)
were prepared from a common C-5 Boc-protected precursor
12 (Scheme 1) to allow divergent derivatization of the C-5
amine after Boc deprotection. Thioglycoside 1929 was reacted
with bromine to afford a mixture of the corresponding glycosyl
bromide and glycal 20. The reaction of the mixture under basic
conditions then afforded glycal 20 in a good overall yield
(78%). Electrophilic fluorination was performed using
Selectfluor in a mixture of H2O/dimethylformamide (DMF)
affording axial-fluoride 21.30 Finally, 21 was acetylated to
afford 12 in a high yield (95%). The Boc inhibitor 12 was
modified in a two-step sequence of Boc deprotection followed
by acylation of the amine. Previously, we reported an
analogous method to prepare nonfluorinated C-5-modified
sialic acid derivatives in a good yield.31 In the case of fluoride
analogue 12, however, the yields of the two-step sequence were
considerably lower (6−90%, Scheme 1). Presumably, the
Figure 1. (a) Working model of metabolic ST inhibitors. The acetylated sialic acid derivative is taken up via passive diffusion and deacetylated by
intracellular esterases. CMP activation in the nucleus by CMAS produces the active inhibitor CMP−SiaFAc, which competitively blocks STs and
induces feedback inhibition of de novo sialic acid biosynthesis. (b) Structure of C-3-fluorinated ST inhibitors 1−18 with C-5 amide or carbamate
modifications.
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presence of the electron-withdrawing fluoride rendered the C-5
amine less reactive, giving rise to various side reactions.
Nevertheless, including precursor 12, a total of 17 derivatives
(2−18) of parent acetamide 1 were prepared. Included are
derivatives 5, 6, and 7 containing an alkyne or azide group
which is amendable for modification using the copper-
catalyzed azide−alkyne cycloaddition (CuAAC) reaction. To
explore whether modifications introduced in this manner are
tolerated in the sialic acid metabolism, derivative 14 was
prepared from 7, using benzyl azide and CuI/tris((1-benzyl-4-
triazolyl)methyl)amine (TBTA).
C-5 Carbamate-Fluorinated Sialic Acids Inhibit
Sialylation with Increased Potency Compared to C-5
Amide Analogues. The inhibitor potency of 1−18 at
different concentrations was first assessed in murine B16-F10
tumor cells using lectins specific for α2,3-linked (MALII, Table
1) or α2,6-linked sialic acids (SNA-I, Table S1). The EC50
values were determined for both linkage types, defined as the
concentration where a 50% decrease in lectin binding
compared to control was observed (Figure 2a,b). Strikingly,
carbamates 7−12 were all more potent inhibitors than
acetamide 1. Carbamate 7 was one of the most active
inhibitors with an average 37-fold increase in potency
compared to the amide analogues. A direct comparison of
carbamate 7 with amide 6 shows a 56-fold increase in
inhibitory potency for the former. Amide 6 only differs from 7
in the substitution of the carbamate oxygen for a CH2. On the
basis of this structural difference, we hypothesize that the
Scheme 1. Synthesis of C-5-Modified ST Inhibitorsa
a(i) Br2, DCM, r.t., 2.5 h; (ii) TEA, DCM, r.t., 16 h, 78% (over two steps); (iii) Selectfluor, 1:3 H2O/DMF, 60 °C, 3 h, 72% (based on recovery);
(iv) Ac2O, py, r.t., 48 h, 95%; (v) TFA, DCM, H2O, r.t., 2 h; (vi) activated acyl substituents (A), TEA, DCM, r.t.; 2: Side product in a reaction of
12 → 11 90%; 3: A = chloroacetyl chloride, 16 h, 60%; 4: A = acetoxyacetyl chloride, 16 h, 43%; 5: A = azidoacetic acid N-hydroxysuccinimide
(NHS) ester, 23 h, 16%; 6: A = 4-pentynoic acid NHS ester, 16 h, 7%; 7: A = N-propargyloxycarbonyl-succinimide, 15 h, 40%; 8: A = allyl
chloroformate, 21.5 h, 16%; 9: A = methyl chloroformate, 16 h, 33%; 10: A = ethyl chloroformate, 16 h, 16%; 11: A = isobutyl chloroformate, 16 h,
33%; 13: A = benzyl chloroformate, 21.5 h, 6%; 15: A = n-butyl chloroformate, 16 h, 32%; 16: A = 2-methoxymethyl chloroformate, 16 h, 90%; 17:
A = 2,2,2-trichloroethoxycarbonyl chloroformate, 16 h, 17%; 18: A = 2-fluoroethyl chloroformate, 16 h, 60%; and (vii) 14: benzyl azide, TBTA,
CuI, Cu, DMF, H2O,
tBuOH, r.t., 16 h, 46%.
Table 1. EC50 Values in Micromolar for Inhibition of α2,3-Linked Sialic Acid
a
aCell lines were cultured for 3 days with 0−204.8 μM amide or carbamate-fluorinated sialic acids or DMSO vehicle control. The cells were stained
with biotinylated MALII lectin that recognizes α2,3-linked sialic acids and streptavidin-PE. Lectin binding was determined by flow cytometry and is
presented as mean percentage lectin binding ±SEM normalized to the control (n = 3). The relative inhibitory potency was calculated for the B16-
F10 cell line by dividing the EC50 of SiaFAc (1) by the EC50 of the compound of interest.
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carbamate group enables an additional binding interaction of
STs resulting in improved inhibition. In line with these
findings, we previously showed that the nonfluorinated
analogue of 7, a carbamate, was better incorporated into the
glycocalyx than the nonfluorinated homologue of 5, an
amide.31 This finding is also supported by a later study on
the metabolic precursor of sialic acid, where an increased
metabolic incorporation was observed for mannosamine
carbamates over amides with the same side chain length.32
In addition to linkage type, linear 2−3 carbon substituents (7,
8, 10, and 18) on the carbamate seem to afford more potent
inhibitors than 1 (9) or 4 (15) carbons, or the introduction of
a more bulky substituent (11−14). In an attempt to modulate
carbamate hydrogen bonding properties, 16−18 were
synthesized, but these did not further improve the inhibitory
effect observed with 7. Chloroacetamide 3 was toxic,
potentially because of its reactive nature. For these reasons,
compounds 3 and 13−18 were not used for subsequent
experiments.
To assess if the improved inhibition of carbamate derivatives
is not restricted to the B16-F10 cell line, the experiments were
extended to human THP-1, HEK293, and HeLa cell lines, as
well as murine 9464D and EL4 cells (Tables 1 and S1). In line
with the findings for B16-F10 cells, the carbamates inhibited
sialylation with significantly higher efficacy compared with the
amide analogues in all of the tested cell lines. Remarkably, the
carbamates also showed good potency in 9464D and EL4
cancer cells that showed very poor sensitivity to the lead
compound 1. Overall, no significant preference was observed
for the inhibition of α2,3-linked (Table 1) over α2,6-linked
sialic acid (Table S1). Next, a toxicity profile of 1−2 and 4−12
was established by monitoring the metabolic activity of cells
after 3 days of treatment. Importantly, none of the compounds
were toxic at concentrations <51.2 μM and most inhibitors
were not even toxic at concentrations as high as 204.8 μM
(Figure S1). Finally, we showed that all sialic acid mimetics
were highly specific as only inhibition of sialylation, but not
overall glycosylation was observed (Figure S2). Altogether,
Figure 2. (a,b) Amide and carbamate-modified fluorinated sialic acids inhibit sialylation of B16-F10 cells. B16-F10 cells were treated with 0.1−
204.8 μM amide (red) or carbamate (blue)-fluorinated sialic acids or dimethyl sulfoxide (DMSO) vehicle control. After 3 days, the cells were
stained with biotinylated MALII (a) or SNA-I (b) that recognize α2,3-linked or α2,6-linked sialic acids, respectively, followed by streptavidin-PE
staining. Binding of lectins was determined by flow cytometry and data are presented as mean percentage lectin binding ± standard error of the
mean (SEM) normalized to the control (n = 3). The EC50 values were extrapolated for all compounds (Tables 1 and S1). (c−f) Recovery of
sialylation after acetamide and carbamate-fluorinated sialic acid treatment. B16-F10 cells were incubated for 3 days with 51.2 μM acetamide or
carbamate-fluorinated sialic acids or DMSO control. Fluorinated sialic acids were removed from the culture and the cells were re-seeded. During a
period of 6 days, sialylation was assessed daily by flow cytometry using MALII or SNA-I lectins. Graphs show recovery of α2,3-sialylation (c,d) or
α2,6-sialylation (e,f) in time presented as mean percentage lectin binding ±SEM normalized to control (n = 3).
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these data indicate that carbamate-modified ST inhibitors can
selectively and potently block sialylation in a dose-dependent
manner without causing cellular toxicity in vitro.
C-5 Carbamate-Fluorinated Sialic Acids Show Long-
Lasting Inhibition of Sialylation. Previously, we found that
the recovery time of sialylation after treatment with 64 μM
SiaFAc (1) was about 2−3 days, whereas the recovery time
after enzymatic sialidase treatment was less than a day.23 To
determine the recovery times of the new amide and carbamate
inhibitors, B16-F10 cells were incubated for 3 days with 51.2
μM fluorinated sialic acids and recovery of sialylation was
monitored over time by lectin staining. Recovery to normal
sialylation levels took approximately 2−3 days for all amide
derivatives (Figure 2c,e) and about 5−6 days for the
carbamates (Figure 3d,f). A prolonged inhibition for
carbamates was also observed at a lower concentration of
25.6 μM (Figure S3). Our previous data showed that
pretreatment of B16-F10 cells with 1 impaired metastasis
formation in vitro and tumor outgrowth in vivo.23,24 Hence, it
will be interesting to further explore the therapeutic potential
of the carbamate-modified ST inhibitors. Altogether, the
improved inhibitory potency combined with the ability to
block sialylation for a prolonged period of time could make C-
5 carbamate-modified ST inhibitors valuable tools in
glycobiology research and potentially in cancer treatment.
C-5 Carbamate-Fluorinated Sialic Acids are More
Efficiently Metabolized to Their CMP Analogue than
the Corresponding Amides. To better understand the
improved potency of the carbamate analogues compared to
their amide counterparts, we performed in silico experiments.
It is well established that fluorinated sialic acids are processed
by CMAS to their corresponding CMP derivatives, which then
act as competitive inhibitors for the donor substrate (CMP−
sialic acid) of all STs. Hence, we first investigated if the
alterations in the C-5 substituents of fluorinated CMP−sialic
acids would be expected to alter binding to STs. Using the
crystal structure of ST6Gal-I as a model, we found that the C-5
substituent is directed into the solvent (Figure 3a). The
nearest residues were between 4.6 and 7.0 Å away from the
acyl carbon atom (oxygen for the carbamates), implying that
differences in ST binding were unlikely to cause the difference
in potency. An alternative explanation holds that the C-5
carbamate derivatives show enhanced CMP activation by
CMAS relative to the C-5 amide analogues. To this end, the
CMP analogues of compounds 1, 6, and 7 were docked into
the crystal structure of murine CMAS, which is almost
completely homologue to human CMAS (Figure 3b−d).
Within the CMAS binding pocket, the C-5 acetyl moiety was
directed toward a hydrophobic cavity (HC) formed by
Leu121, Ile124, Tyr216, and Leu22833 (Figure 3b), which in
the crystal structure held the natural methyl group, but is big
enough to fit larger moieties. Additionally, Ser120 and Gln141
formed a hydrophilic cavity. Gln141 made polar interactions
with N5 (N-acetyl) and O8 and Ser120 with the N-acetyl
carbonyl oxygen (Figure 3b). Modeling amide and carbamate
modifications into the CMAS crystal structure indicated that
additional interactions of the carbamates with this hydrophilic
gate could arise. As shown for CMP−SiaFPen 6 (Figure 3c)
and CMP−SiaFPoc 7 (Figure 3d), the alkoxy oxygen of the
carbamate could make an additional polar interaction with
Ser120. The C-5 carbamate derivatives may therefore have a
lower KM leading to a higher Kcat/KM and increased
intracellular concentrations of the fluorinated CMP sialic
acids. The increased concentration is expected to improve ST
inhibition as well as feedback inhibition of the de novo sialic
acid biosynthesis.
To confirm this hypothesis, the metabolic efficiency of the
SiaFR derivatives toward their CMP-activated analogues by
CMAS in time was established. To this end, intracellular
CMP−SiaFR levels were analyzed in B16-F10 cells treated for
different time points with SiaFR derivatives using reverse-phase
ion pairing chromatography coupled to a triple quadrupole
mass spectrometer operating in negative ion mode (Figure 4).
These experiments revealed a more efficient conversion of the
carbamate-based inhibitors SiaFPoc (7) and SiaFEt (10), over
amides SiaFAc (1) and SiaFPen (6) (Figure 4a). The
carbamate-based inhibitors also decreased the intracellular
CMP−Sia pool faster than the amides (Figure 4b). These
observations were consistent with the improved potency of the
carbamate-based inhibitors (Table 1) as well as the in silico
experiments (Figure 3). We therefore conclude that the
improved potency of the C-5 carbamate-based inhibitors over
the amides is due to a more efficient metabolism into the
respective CMP analogues, yielding higher concentrations of
the active inhibitor acting on STs and GNE.
■ CONCLUSIONS
Sialic acids are involved in numerous biological processes
ranging from neuronal development to immune cell trafficking.
However, sialic acids are also the targets of several pathogens
Figure 3. (a) CMP−SiaFAc (from 5BO9, green carbons) was
superposed onto cocrystalized CMP in the ST6Gal-I binding pocket
(4JS2, white carbons and surface). Distances (Å) to nearest residues
Gln235, Tyr354, and Phe359 are indicated with black dashes. (b)
Cocrystalized CMP−Sia (green carbons) in the CMAS binding
pocket (1QWJ, domain D, white carbons). Between the HC (Leu121,
Ile124, Tyr216, and Leu228) and the sialic acid pyranose ring, there is
a hydrophilic gate (Ser120, Gln141, pink carbons). Hydrogen bonds
are depicted with orange lines. (c,d) Energy-minimized poses of
SiaFPen (6) [green carbons, (c)] and SiaFPoc (7) [green carbons,
(d)] in the CMAS binding pocket (1QWJ, domain D, white carbons).
Hydrogen bonds are depicted with orange lines. The hydrophilic gate
accommodates the carbamate [SiaFPoc, (d)] more favorably than the
amide [SiaFPen, (c)] because of an additional polar interaction with
Ser120.
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and aberrant sialylation of cancer cells mediates immune
evasion, migration and metastasis. The highly effective
inhibitors developed in this study are therefore interesting
tools to study the broad biological functions of sialic acid
sugars. Additionally, their specificity, high potency and
prolonged inhibition qualifies them as good candidates for
further therapeutic development. We showed that the
carbamate based inhibitors are more efficiently metabolized
towards their active CMP analogues, thereby reaching higher
effective inhibitor concentrations inside cells. This mechanism
could also be considered in the design of other sialylation
inhibitors, as well as metabolic labeling reagents that utilize the
same enzymatic machinery.
■ EXPERIMENTAL SECTION
1H and 13C NMR spectra were recorded on a Varian Inova 400 MHz
or a Bruker AVANCE III 500 MHz spectrometer. The purity of the
compounds (≥95%) was determined by nuclear magnetic resonance
(NMR) spectroscopy. Mass spectra were recorded on a JEOL JMS-
T100CS AccuTOF mass spectrometer. Automatic column chroma-
tography was performed on Biotage Isolera Spektra One, using SNAP
cartridges 10−50 g filled with normal silica (Biotage, 30−100 μm, 60
Å). TLC analysis was conducted on TLC silica gel, 60, F254, Merck,
with detection by UV absorption (254 nm) where applicable and by
spraying with 20% H2SO4 in MeOH followed by charring at ∼150 °C.
Dichloromethane (DCM) was freshly distilled. All reactions were
carried out under an argon atmosphere.
General Procedure for the Preparation of SiaFR (2−13, 15−
18). Boc inhibitor 12 (50 mg; 82 μmol) was dissolved in a 1:1:2
mixture of respectively DCM, H2O, and trifluoroacetic acid (TFA)
(1.6 mL; 0.05 M). The mixture was stirred for 2 h at room
temperature (r.t.) (TLC: (EtOAc/hept, 60:40 v/v) Rf = 0.09). The
mixture was then diluted with H2O and concentrated in vacuo. The
residue was dissolved in DCM (0.83 mL; 0.1 M) and successively
activated acyl substituents (497 μmol; 6 equiv) and triethylamine
(TEA) (35 μL; 248 μmol; 3 equiv) were added. After stirring at r.t.
for 16 h, the mixture was diluted with DCM and washed successively
with aq HCl (0.1 M) and sat. aq NaHCO3. The organic layer was
dried over MgSO4, filtered, and concentrated in vacuo. Silica gel flash
column chromatography (EtOAc in hept) afforded SiaFR 2−13, 15−
18 (6−90%). Variations on this protocol can be found in the
Supporting Information.
Methyl 5-(tert-Butoxycarbamado)-2,4,7,8,9-penta-O-acetyl-
3,5-dideoxy-3-fluoro-D-glycero-β-galacto-non-2-ulopyranoso-
nate (12). To a solution of 21 (789 mg; 1.39 mmol) in py (12 mL;
148 mmol; 107 equiv), Ac2O (6 mL; 63.6 mmol; 45.7 equiv) was
slowly added. After stirring at r.t. for 24 h, the mixture was
concentrated in vacuo using Tol for coevaporation. The residue was
dissolved in EtOAc and washed successively with aq HCl (0.1 M) and
sat. aq NaHCO3. The organic layer was dried over MgSO4, filtered,
and concentrated in vacuo. Silica gel flash column chromatography (0
→ 50% EtOAc in hept) afforded 12 (717 mg; 1.176 mmol; 95%) as a
white foam.
Me t h y l 5 - [ ( 1 - B e n z y l - 1H - 1 , 2 , 3 - t r i a z o l - 4 - y l ) -
methylcarbamado]-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (14). To a
mixture of 7 (10 mg; 17 μmol) in a 1:9 mixture of H2O and
tBuOH
(0.19 mL; 0.09 M), Bn-N3 (4.5 mg; 34 μmol; 2 equiv) was added. A
premixture of TBTA (29 mg), DMF (750 μL), and CuI (5.1 mg) was
agitated until a homogeneous solution was obtained. The TBTA
mixture (95 μL) was added to the H2O/
tBuOH mixture and 10 mg of
copper flakes was added. The reaction was stirred at r.t. for 16 h,
filtered, and concentrated in vacuo. Silica gel flash column
chromatography (0 → 80% EtOAc in hept) afforded 14 (5.7 mg;
17 μmol; 46%) as a white solid.
Methyl 5-(tert-Butoxycarbamado)-4,7,8,9-tetra-O-acetyl-
2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-non-2-enonate
(20). To a solution of 1931 (2.757 g; 4.22 mmol) in DCM (42.2 mL;
0.1 M), Br2 (0.239 mL; 4.64 mmol; 1.1 equiv) was slowly added. After
2.5 h of stirring at r.t., the reaction was diluted with DCM and washed
with 10% aq Na2S2O3. The milky organic layer was dried over MgSO4,
filtered, and the clear filtrate was extracted once more with 10% aq
Na2S2O3 before drying over MgSO4 and filtering. The filtrate was
concentrated in vacuo, dissolved in DCM (42.0 mL; 0.1 M), and TEA
(1.699 g; 16.79 mmol; 4 equiv) was added. The reaction was stirred
for 16 h at r.t. and concentrated in vacuo. The residue was dissolved
in EtOAc and washed successively with aq HCl (0.1 M) and sat. aq
NaHCO3. The organic layer was dried over MgSO4, filtered, and again
concentrated in vacuo. Silica gel flash column chromatography (0 →
45% EtOAc in hept) afforded 20 (1.734 g; 3.26 mmol; 78% two
steps) as a white solid.
Methyl 5-(tert-Butoxycarbamado)-4,7,8,9-penta-O-acetyl-
3,5-dideoxy-3-fluoro-D-glycero-β-galacto-non-2-ulopyranoso-
nate (21). To a solution of 20 (1.724 g; 3.24 mmol) in a 1:3 mixture
of H2O and DMF (32 mL; 0.1 M), Selectfluor (3.45 g; 9.73 mmol; 3
equiv) was added. The reaction was stirred at 60 °C for 3 h, quenched
with sat. aq NaHCO3, and concentrated in vacuoeven though
conversion was incomplete. The residue was dissolved in EtOAc and
washed successively with aq. HCl (0.1 M) and sat. aq NaHCO3. The
organic layer was dried over MgSO4, filtered, and concentrated in
vacuo. Silica gel flash column chromatography (0 → 50% EtOAc in
hept) afforded 21 (789 mg; 1.39 mmol; 72% based on the recovery of
the starting material) as a white foam.
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quadrupole mass spectrometer operating in negative ion mode and presented as their abundance in the nucleotide sugar pool ±SEM (n = 2).
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after treatment with 25.6 μM fluorinated sialic acid
mimetics, and EC50 values for inhibition of α2,6-linked
sialic acid; and molecular formula strings (PDF)
(CSV)
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